Jeil PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 5/6
Jeil PharmaceuticalLtd has a total shareholder equity of ₩183.8B and total debt of ₩71.2B, which brings its debt-to-equity ratio to 38.7%. Its total assets and total liabilities are ₩493.1B and ₩309.4B respectively.
Key information
38.7%
Debt to equity ratio
₩71.17b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩37.58b |
| Equity | ₩183.75b |
| Total liabilities | ₩309.35b |
| Total assets | ₩493.10b |
Recent financial health updates
Is Jeil PharmaceuticalLtd (KRX:271980) A Risky Investment?
Nov 14
Is Jeil PharmaceuticalLtd (KRX:271980) Using Too Much Debt?
Apr 11Recent updates
Is Jeil PharmaceuticalLtd (KRX:271980) A Risky Investment?
Nov 14Jeil Pharmaceutical Co.,Ltd's (KRX:271980) Business And Shares Still Trailing The Industry
Sep 08Is Jeil PharmaceuticalLtd (KRX:271980) Using Too Much Debt?
Apr 11Solid Earnings May Not Tell The Whole Story For Jeil PharmaceuticalLtd (KRX:271980)
Mar 19Financial Position Analysis
Short Term Liabilities: A271980's short term assets (₩324.2B) exceed its short term liabilities (₩296.5B).
Long Term Liabilities: A271980's short term assets (₩324.2B) exceed its long term liabilities (₩12.9B).
Debt to Equity History and Analysis
Debt Level: A271980's net debt to equity ratio (18.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A271980's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A271980 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A271980 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 18.4% per year.